Objective: To determine whether hyperinsulinism affects cytochrome P450c 17\g=a\ activity by investigating the correlation between 17\p=n-\hydroxyprogesterone (17\p=n-\OHP) hyper-responsiveness to the gonadotropin-releasing hormone (GnRH) 
Introduction
The women with polycystic ovary syndrome (PCOS) have a high 17-hydroxyprogesterone (17-OHP) response to gonadotropin-releasing hormone (GnRH) agonist testing with nafarelin (1) or buserelin (2) . It (by 17a-hydroxylase activity) and 17-OHP is converted to androstenedione (by 17,20-lyase activity) (3) .
PCOS is also associated with insulin resistance and hyperinsulinemia (4) . Hyperinsulinemia and elevated luteinizing hormone (LH), acting synergistically, result in increased ovarian androgen production (5, 6) . Insulin resistance may be involved in the pathogenesis of PCOS, but the actual role of hyperinsulinemia in the development of PCOS and the precise relationship between insulin and androgen secretion have not yet been clarified. The nature of dysregulation of the cytochrome P4 5 Oc 17 enzyme is unclear.
The aim of this study was to evaluate in an adequate number of patients the relationship between the 17-OHP response to buserelin testing and hyperinsulin¬ emia, and the role of insulin in the dysregulation of the cytochrome P450cl7a enzyme in PCOS.
Patients and methods
The study was 18 normal women has been accepted as the cut-off level of peak value (6-45 + (2 1-42) = 9-29 nmol/1). During the OGTT, although the mean glucose levels at 0, 30, 60 and 120 min were significantly higher in PCOS patients than in controls (P < 0-05), the glucose levels under basal conditions and postprandially in all study subjects were within the normal range. Basal insulin levels were elevated in PCOS patients compared with those in controls, while basal C-peptide levels were similar (P > 0-05). The PCOS patients showed signifi¬ cantly higher mean post-glucose load insulin ( Fig. 1) and C-peptide levels ( Fig. 2 Table 3 . No significant correlations were found between basal 17-OHP and fasting insulin or fasting C-peptide, between peak 17-OHP and fasting insulin, peak insulin or peak C-peptide, between AUC 17-OHP and insulin AUC or C-peptide AUC, and between percent increment in 17-OHP and insulin AUC or C-peptide AUC (P> 0-05). We have also examined the findings of 19 patients with oligo/amenorrhea remaining after exclud¬ ing eumenorrheic patients. No significant correlations were seen between basal 17-OHP and fasting insulin (r: 0-283) or fasting C-peptide (r: 0-095), between peak 17-OHP and peak insulin (r: 0-042) or peak C-peptide (r: 0-112), between percent increment in 17-OHP and peak insulin (r: 0-139) or peak C-peptide (r: 0-025), and between 17-OHP AUC and insulin AUC (r: 0-097) or C-peptide AUC (r: 0-085) in PCOS patients with oligo/amenorrhea (P > 0-05).
Discussion
In several studies, the presence of insulin resistance in both obese and non-obese patients with PCOS (11, 12) and significant positive correlations between insulin and androgen levels have been demonstrated (13) .
These studies support a primary role of insulin resistance in the pathogenesis of ovarian hyperandrogenism and PCOS. In contrast to these data, some other studies showed no positive correlation between insulin and androgen levels in PCOS women (14) (15) (16) (17) . Also, studies using hyperinsulinemic euglycemic clamps that permit the maintenance of hyperinsulinemia for several hours did not show a consistent effect of the elevated insulin levels on androgen production in women with PCOS (18, 19) . So, the relation between hyperandrogenemia and hyperinsulinemia is still not clear.
Since a large proportion of the insulin released by the /3-cell is metabolized by the liver before reaching the systemic circulation (20) , peripheral insulin levels are not a good marker of endogenous insulin secretion. The plasma C-peptide assay may be a more reliable parameter of pancreatic secretion of insulin than the immunoreactive insulin assay (21) . In the present study the PCOS patients showed significantly higher mean basal insulin and higher mean post-glucose load insulin and C-peptide levels than controls similar to that previously reported in women with PCOS (22, 23) . 
